Analysts Rate LeMaitre Vascular as “Moderate Buy” Amid Market Activity

LeMaitre Vascular, Inc. (NASDAQ: LMAT) has received a consensus recommendation of “Moderate Buy” from eight research firms currently analyzing the company. This assessment includes four analysts who rate the stock as a hold and four who recommend a buy. The average price target set by these brokers stands at **$100.20** for the next year, indicating a positive outlook for the company’s stock.

Recent Analyst Activity

LeMaitre Vascular has been the subject of several analyst reports recently. On **November 5, 2023**, Roth Capital reaffirmed a “buy” rating, setting a price target of **$108.00**. Conversely, Wells Fargo & Company revised its target price down from **$97.00** to **$93.00**, maintaining an “equal weight” rating. Barrington Research also reiterated an “outperform” rating with a target of **$95.00** on **October 15, 2023**. In a contrasting move, Zacks Research downgraded the stock from a “strong-buy” to a “hold” rating on **January 1, 2023**, and Wall Street Zen similarly reduced its rating to a hold on **December 6, 2022**.

Performance and Financials

On **November 6, 2023**, LeMaitre Vascular reported its quarterly earnings, revealing an **earnings per share (EPS)** of **$0.62**, surpassing analysts’ expectations of **$0.57** by **$0.05**. The company achieved a net margin of **22.14%** and a return on equity of **14.06%**. Revenue for the quarter totaled **$61.05 million**, slightly below the forecast of **$62.18 million**. This represents an increase of **11.4%** compared to the same quarter in the previous year.

The stock opened at **$88.27** on **November 7, 2023**, with a **52-week low** of **$71.42** and a **high** of **$105.55**. LeMaitre Vascular boasts a market capitalization of **$2.00 billion**, a price-to-earnings ratio of **38.05**, and a PEG ratio of **1.96**. The company’s financial health is reflected in its debt-to-equity ratio of **0.44** and a robust liquidity position, indicated by a quick ratio of **11.45** and a current ratio of **13.58**.

Looking ahead, LeMaitre Vascular has provided guidance for the fiscal year **2025**, anticipating an EPS between **$2.480** and **$2.530**, with a fourth-quarter estimate of **$0.640** to **$0.690**.

In addition, the firm announced a quarterly dividend of **$0.20** per share, which was paid on **December 4, 2023**. Shareholders of record as of **November 20, 2023**, received this dividend, translating to an annualized yield of **0.9%**. The company’s dividend payout ratio stands at **34.48%**.

LeMaitre Vascular, based in **Burlington, Massachusetts**, specializes in developing and marketing medical devices for the treatment of peripheral vascular disease. Founded in **1983** by **George D. LeMaitre**, the company offers a comprehensive range of vascular surgical instruments, grafts, patches, and embolic protection devices, catering to the needs of cardiovascular surgeons and interventional specialists.

This summary highlights the current standing and future potential of LeMaitre Vascular in the healthcare market, reflecting the insights of industry analysts and recent financial performance.